[Controlled clinical study on 49 patients of SARS treated by integrative Chinese and Western medicine].
OBJECTIVE
To evaluate the efficacy of Integrative Chinese and western medicine (ICWM) in treating SARS.


METHODS
By controlled paralled design, 49 patients of SARS were studied, they were divided into the control group (n = 29) and the ICWM group (n = 20). The former was treated according to the "Recommended Program for Treatment of SARS" provided by Health Ministry, by administering of such drugs as Ribavirin, Levofloxacin, Thymopentin, Azithromycin, etc, the latter was treated with the ICWM protocol for SARS of "Special Technological Action to Prevent and Treat SARS" provided by Science and Technology Ministry.


RESULTS
(1) The time for improving symptom in the ICWM group was 5.10 days and that in the control group was 7.62 days, the difference between them was significant (P < 0.05); (2) The days and amount for use hormone before subtract in the two group were similar, with insignificant difference (P > 0.05); (3) The days and amount for use hormone after subtract in the two groups were significantly different (P < 0.05); (4) The time for improving peripheral WBC count and absolute value of lymphocyte, as well as for absorption time of shadow in chest film were not different significantly between the two groups (P > 0.05).


CONCLUSIONS
In treating SARS, ICWM was superior to the treatment with western medicine alone in aspects of improving clinical symptom, promoting recovery of immune function and absorption of lung inflammation, decreasing the dosage of hormone used and shortening the therapeutic course.
Zhang
Rui-lin
RL
Medical Group, Wangjing Hospital, Chian Academy of Traditional Chinese Medicine Stationed in Chaoyang Women and Children Hospital Fixed for SARS, Beijing 100102.
Jiao
Qiang
Q
Wang
Bao-guo
BG
D000293:Adolescent; D000328:Adult; D000368:Aged; D004359:Drug Therapy, Combination; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D064704:Levofloxacin; D008297:Male; D008775:Methylprednisolone / Q000627:therapeutic use*; D008875:Middle Aged; D015242:Ofloxacin / Q000627:therapeutic use; D008517:Phytotherapy; D012254:Ribavirin / Q000627:therapeutic use*; D045169:Severe Acute Respiratory Syndrome / Q000188:drug therapy* / Q000276:immunology
D004365:Drugs, Chinese Herbal; D012254:Ribavirin; D064704:Levofloxacin; D015242:Ofloxacin; D008775:Methylprednisolone